Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

Baker McKenzie Advises Merit Medical on the Acquisition of View Point Medical

Дата публикации: 07-04-2026 00:00:00



Основное содержимое страницы с новостью.

Baker McKenzie represented Merit Medical Systems, Inc. (NASDAQ: MMSI), a global healthcare technology company, on its acquisition of View Point Medical, Inc., a privately held medical device company based in Carlsbad, California. The aggregate consideration was approximately USD 140 million, including USD 90 million in cash at closing and two deferred payments of USD 25 million each payable on the first and second anniversaries of closing.

The deal expands Merit’s therapeutic oncology portfolio with View Point’s OneMark® Detection Imaging System and OneMark® Tissue Markers, FDA cleared technologies that enhance lesion localization at the time of biopsy and complement Merit’s existing SCOUT® platform.

Led by M&A Partner Lewis Popoff, the team included: 

  • Corporate / M&A: Jeanne Song, Rachel Gray and Noah Walusis (Chicago)
  • Commercial:  Michelle Carr (Chicago)
  • Intellectual Property: Jessica Greenwald (Dallas)
  • FDA Regulation: Xin Tao and Lois Sheng Liu (Washington, DC)
  • Tax: Ross Staine (Houston)
  • Benefits & Executive Compensation: Chris Guldberg (Chicago)
  • Employment: Kimberly Franko Lower (New York) and Loïc Coutelier (Palo Alto)

Learn more about the transaction: Merit Medical Acquires View Point Medical, Inc.

With more than 2,700 deal practitioners across 40+ jurisdictions, Baker McKenzie has the broadest footprint of any law firm and is recognized for seamlessly executing complex, cross border transactions. The Firm’s Healthcare & Life Sciences group is among the largest globally, drawing on six decades of sector knowledge to provide comprehensive legal services in transactions, regulatory investigations, and disputes across its global network.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Baker McKenzie Advises on Memo Therapeutics' Sale to Ipsen and Related Carve-Out018.3301-07-2026
2Baker McKenzie Advises Chemomab on Merger with Scipher Medicine01010-07-2026
3Baker McKenzie advises on the sale of Vitabiotics to Bain Capital01027-07-2026
4Baker McKenzie Advises Bayer on USD 2.45 billion Acquisition of Perfuse Therapeutics018.3306-05-2026
5Baker McKenzie Advises Servier on the Acquisition of Day One Biopharmaceuticals for Approximately USD 2.5 Billion016.2510-03-2026
6Baker McKenzie Advises Bain Capital Life Sciences on Investment in Swixx BioPharma01005-06-2026
7Baker McKenzie has advised STADA on the acquisition of rights to Locobase® from Karo Healthcare01005-05-2026
8Baker McKenzie Advises Joint Bookrunners on Sunway Healthcare’s MYR 3.28 Billion IPO018.3318-03-2026
9Baker McKenzie Advises a Consortium led by SPE Capital, and included EBRD, Proparco and BIO on their Investment in Leading Ophthalmic Pharmaceutical Manufacturer09.1501-04-2026
10Baker McKenzie Acts as Global Counsel to Medtronic plc on the Carve-out and Spin-off of their Diabetes business, MiniMed Group, Inc. 019.5211-03-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.4. Источник: www.bakermckenzie.com.